|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ridge CA, McErlean AM and Ginsberg MS:
Epidemiology of lung cancer. Semin Intervent Radiol. 30:93–98.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Molina JR, Yang P, Cassivi SD, Schild SE
and Adjei AA: Non-small cell lung cancer: Epidemiology, risk
factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang L: Adaptive evolution and frequent
gene conversion in the brain expressed X-linked gene family in
mammals. Biochem Genet. 46:293–311. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Alvarez E, Zhou W, Witta SE and Freed CR:
Characterization of the Bex gene family in humans, mice, and rats.
Gene. 357:18–28. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xiao Q, Hu Y, Liu Y, Wang Z, Geng H, Hu L,
Xu D, Wang K, Zheng L, Zheng S and Ding K: BEX1 promotes
imatinib-induced apoptosis by binding to and antagonizing BCL-2.
PLoS One. 9:e917822014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Vilar M, Murillo-Carretero M, Mira H,
Magnusson K, Besset V and Ibáñez CF: Bex1, a novel interactor of
the p75 neurotrophin receptor, links neurotrophin signaling to the
cell cycle. EMBO J. 25:1219–1230. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhou X, Meng Q, Xu X, Zhi T, Shi Q, Wang Y
and Yu R: Bex2 regulates cell proliferation and apoptosis in
malignant glioma cells via the c-Jun NH2-terminal kinase pathway.
Biochem Biophys Res Commun. 427:574–580. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lindblad O, Li T, Su X, Sun J, Kabir NN,
Levander F, Zhao H, Lu G, Rönnstrand L and Kazi JU: BEX1 acts as a
tumor suppressor in acute myeloid leukemia. Oncotarget.
6:21395–21405. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ding K, Su Y, Pang L, Lu Q, Wang Z, Zhang
S, Zheng S, Mao J and Zhu Y: Inhibition of apoptosis by
downregulation of hBex1, a novel mechanism, contributes to the
chemoresistance of Bcr/Abl+ leukemic cells. Carcinogenesis.
30:35–42. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Geng HT, Cheng ZW, Cao RJ, Wang ZB, Xing
SZ, Guo C, Wang F, Liu CM, Chen SS and Cheng YF: Low expression of
BEX1 predicts poor prognosis in patients with esophageal squamous
cell cancer. Oncol Rep. 40:2778–2787. 2018.PubMed/NCBI
|
|
13
|
Karakoula K, Jacques TS, Phipps KP,
Harkness W, Thompson D, Harding BN, Darling JL and Warr TJ:
Epigenetic genome-wide analysis identifies BEX1 as a candidate
tumour suppressor gene in paediatric intracranial ependymoma.
Cancer Lett. 346:34–44. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hu Y, Xiao Q, Chen H, He J, Tan Y, Liu Y,
Wang Z, Yang Q, Shen X, Huang Y, et al: BEX2 promotes tumor
proliferation in colorectal cancer. Int J Biol Sci. 13:286–294.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nie E, Zhang X, Xie S, Shi Q, Hu J, Meng
Q, Zhou X and Yu R: B-catenin is involved in Bex2 down-regulation
induced glioma cell invasion/migration inhibition. Biochem Biophys
Res Commun. 456:494–499. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Naderi A, Teschendorff AE, Beigel J,
Cariati M, Ellis IO, Brenton JD and Caldas C: BEX2 is overexpressed
in a subset of primary breast cancers and mediates nerve growth
factor/nuclear factor-kappaB inhibition of apoptosis in breast
cancer cell lines. Cancer Res. 67:6725–6736. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tong X, Xie D, Roth W, Reed J and Koeffler
HP: NADE (p75NTR-associated cell death executor) suppresses
cellular growth in vivo. Int J Oncol. 22:1357–1362.
2003.PubMed/NCBI
|
|
18
|
Yoon K, Jang HD and Lee SY: Direct
interaction of Smac with NADE promotes TRAIL-induced apoptosis.
Biochem Biophys Res Commun. 319:649–654. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chien J, Staub J, Avula R, Zhang H, Liu W,
Hartmann LC, Kaufmann SH, Smith DI and Shridhar V: Epigenetic
silencing of TCEAL7 (Bex4) in ovarian cancer. Oncogene.
24:5089–5100. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gao W, Li JZ, Chen SQ, Chu CY, Chan JY and
Wong TS: Decreased brain-expressed X-linked 4 (BEX4) expression
promotes growth of oral squamous cell carcinoma. J Exp Clin Canc
Res. 35:922016. View Article : Google Scholar
|
|
21
|
Zhu XF, Zhu BS, Wu FM and Hu HB: DNA
methylation biomarkers for the occurrence of lung adenocarcinoma
from TCGA data mining. J Cell Physiol. 233:6777–6784. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhao Z, Li J, Tan F, Gao S and He J: mTOR
up-regulation of BEX4 promotes lung adenocarcinoma cell
proliferation by potentiating OCT4. Biochem Bioph Res Commun.
500:302–309. 2018. View Article : Google Scholar
|
|
23
|
Goldman M, Craft B, Hastie M, Repečka K,
Kamath A, McDade F, Rogers D, Brooks AN, Zhu Z and Haussler D: The
UCSC Xena platform for public and private cancer genomics data
visualization and interpretation. bioRxiv. 3264702019.
|
|
24
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Garber ME, Troyanskaya OG, Schluens K,
Petersen S, Thaesler Z, Pacyna-Gengelbach M, van de Rijn M, Rosen
GD, Perou CM, Whyte RI, et al: Diversity of gene expression in
adenocarcinoma of the lung. Proc Natl Acad Sci USA. 98:13784–13789.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Okayama H, Kohno T, Ishii Y, Shimada Y,
Shiraishi K, Iwakawa R, Furuta K, Tsuta K, Shibata T, Yamamoto S,
et al: Identification of genes upregulated in ALK-positive and
EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res.
72:100–111. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bhattacharjee A, Richards WG, Staunton J,
Li C, Monti S, Vasa P, Ladd C, Beheshti J, Bueno R, Gillette M, et
al: Classification of human lung carcinomas by mRNA expression
profiling reveals distinct adenocarcinoma subclasses. Proc Natl
Acad Sci USA. 98:13790–13795. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hou J, Aerts J, den Hamer B, van Ijcken W,
den Bakker M, Riegman P, van der Leest C, van der Spek P, Foekens
JA, Hoogsteden HC, et al: Gene expression-based classification of
non-small cell lung carcinomas and survival prediction. PLoS One.
5:e103122010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Selamat SA, Chung BS, Girard L, Zhang W,
Zhang Y, Campan M, Siegmund KD, Koss MN, Hagen JA, Lam WL, et al:
Genome-scale analysis of DNA methylation in lung adenocarcinoma and
integration with mRNA expression. Genome Res. 22:1197–1211. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Landi MT, Dracheva T, Rotunno M, Figueroa
JD, Liu H, Dasgupta A, Mann FE, Fukuoka J, Hames M, Bergen AW, et
al: Gene expression signature of cigarette smoking and its role in
lung adenocarcinoma development and survival. PLoS One.
3:e16512008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Imielinski M, Berger AH, Hammerman PS,
Hernandez B, Pugh TJ, Hodis E, Cho J, Suh J, Capelletti M,
Sivachenko A, et al: Mapping the hallmarks of lung adenocarcinoma
with massively parallel sequencing. Cell. 150:1107–1120. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cancer Genome Atlas Research Network, .
Comprehensive molecular profiling of lung adenocarcinoma. Nature.
511:543–550. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu J, Lichtenberg T, Hoadley KA, Poisson
LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee
AV, et al: An integrated TCGA pan-cancer clinical data resource to
drive high-quality survival outcome analytics. Cell.
173:400–416.e11. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Han F, Zhang MQ, Liu WB, Sun L, Hao XL,
Yin L, Jiang X, Cao J and Liu JY: SOX30 specially prevents
Wnt-signaling to suppress metastasis and improve prognosis of lung
adenocarcinoma patients. Respir Res. 19:2412018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Han F, Liu W, Jiang X, Shi X, Yin L, Ao L,
Cui Z, Li Y, Huang C, Cao J and Liu J: SOX30, a novel epigenetic
silenced tumor suppressor, promotes tumor cell apoptosis by
transcriptional activating p53 in lung cancer. Oncogene.
34:4391–4402. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Heckman-Stoddard BM: Oncology biomarkers:
Discovery, validation, and clinical use. Semin Oncol Nurs.
28:93–98. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Goossens N, Nakagawa S, Sun X and Hoshida
Y: Cancer biomarker discovery and validation. Transl Cancer Res.
4:256–269. 2015.PubMed/NCBI
|
|
40
|
Fischer C, Drexler HG, Reinhardt J,
Zaborski M and Quentmeier H: Epigenetic regulation of brain
expressed X-linked-2, a marker for acute myeloid leukemia with
mixed lineage leukemia rearrangements. Leukemia. 21:374–377. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Foltz G, Ryu GY, Yoon JG, Nelson T, Fahey
J, Frakes A, Lee H, Field L, Zander K, Sibenaller Z, et al:
Genome-wide analysis of epigenetic silencing identifies BEX1 and
BEX2 as candidate tumor suppressor genes in malignant glioma.
Cancer Res. 66:6665–6674. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Williams JL, Greer PA and Squire JA:
Recurrent copy number alterations in prostate cancer: An in silico
meta-analysis of publicly available genomic data. Cancer Genet.
207:474–488. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
De Carvalho DD, Sharma S, You JS, Su SF,
Taberlay PC, Kelly TK, Yang X, Liang G and Jones PA: DNA
methylation screening identifies driver epigenetic events of cancer
cell survival. Cancer Cell. 21:655–667. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Black JC, Manning AL, Van Rechem C, Kim J,
Ladd B, Cho J, Pineda CM, Murphy N, Daniels DL, Montagna C, et al:
KDM4A lysine demethylase induces site-specific copy gain and
rereplication of regions amplified in tumors. Cell. 154:541–555.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Licht JD: DNA methylation inhibitors in
cancer therapy: The immunity dimension. Cell. 162:938–939. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Xiao Q, Zhou D, Rucki AA, Williams J, Zhou
J, Mo G, Murphy A, Fujiwara K, Kleponis J, Salman B, et al:
Cancer-associated fibroblasts in pancreatic cancer are reprogrammed
by tumor-induced alterations in genomic DNA methylation. Cancer
Res. 76:5395–5404. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kamel HFM and Al-Amodi HSAB: Exploitation
of gene expression and cancer biomarkers in paving the path to era
of personalized medicine. Genomics Proteomics Bioinformatics.
15:220–235. 2017. View Article : Google Scholar : PubMed/NCBI
|
